Compare Rush Street Interactive Inc (RSI) vs Summit Therapeutics Inc (SMMT) Price & Performance

Rush Street Interactive (RSI) trades at $34.52, up 6.22% in 24 hours, with strong bullish momentum from technical indicators and recent earnings beats. The stock shows robust revenue growth, reaching $1.13B in 2025, and maintains a 76.92% buy rating from analysts. Positive sentiment is fueled by expansion news, such as the BetRivers launch in Alberta (GlobeNewsWire, 2026-07-13).

Outlook remains positive with earnings growth as a key catalyst, though high valuation multiples (P/E 101.53) and overbought RSI levels pose risks. The consensus price target of $31.11 suggests potential downside, but institutional bullishness and operational cash flow strength support long-term upside if execution continues.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.